Methyl 3,4-dihydroxybenzoate
Based on 1 Customer Validation
Methyl 3,4-dihydroxybenzoate (Protocatechuic acid methyl ester; Methyl protocatechuate) is a major metabolite of antioxidant polyphenols found in green tea. Antioxidant and anti-inflammatory effect.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.50%
- CAS. Nr.: 2150-43-8
- Formel: C8H8O4
- Molecular Weight:168.15
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-12212
OmaveloxoloneNrf2 Activator -
HY-100523
ML385Nrf2 Inhibitor -
HY-Z0548R
Methyl 3,4-dihydroxybenzoate (Standard) -
HY-19543
BrusatolNrf2 Inhibitor -
HY-N1902
4-Hydroxyphenylacetic acidEndogenous Metabolite -
HY-B2230
HinokitiolVirus Protease Inhibitor -
HY-120912
Gingerenone ANrf2-Gpx4 Activator -
HY-N0162
LuteolinNrf2 Inhibitor -
HY-N1902R
4-Hydroxyphenylacetic acid (Standard)Endogenous Metabolite -
HY-13755
SulforaphaneKeap1/Nrf2/ARE Inducer -
HY-17376
EzetimibeCholesterol Absorption Inhibitor -
HY-133114
Ezetimibe ketoneNrf2 Activator/ROS Inhibitor
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BMDM | IC50 |
78 μM
Compound: Table 1, R18C1
|
Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base
Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base
|
[PMID: 31257875] |
| MDCK | CC50 |
>183.07 μM
Compound: 3a
|
Cytotoxicity against MDCK cells after 72 hrs by MTT assay
Cytotoxicity against MDCK cells after 72 hrs by MTT assay
|
[PMID: 24803363] |
| MDCK | IC50 |
18.27 μM
Compound: 3a
|
Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 2 to 3 days by crystal violet staining-based plaque reduction assay
Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 2 to 3 days by crystal violet staining-based plaque reduction assay
|
[PMID: 24803363] |
| P388 | ED50 |
1.4 μg/mL
Compound: 11
|
Growth inhibition of mouse P388 cells
Growth inhibition of mouse P388 cells
|
[PMID: 10650082] |
In Vitro
Methyl 3,4-dihydroxybenzoate (Protocatechuic acid methyl ester; Methyl protocatechuate) alleviates the toxic effects of F- via modulating its bioavailability, intracellular calcium level, mitochondrial membrane integrity and redox signaling in A549 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 2150-43-8
-
Appearance Solid
-
Molecular Weight 168.15
-
Formel C8H8O4
-
Color White to off-white
-
SMILES
O=C(OC)C1=CC=C(O)C(O)=C1
-
Synonyms
Protocatechuic acid methyl ester; Methyl protocatechuate
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 50 mg/mL (297.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (14.87 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (14.87 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Ameeramja J, et al. Protocatechuic acid methyl ester ameliorates fluoride toxicity in A549 cells. Food Chem Toxicol. 2017 Nov;109(Pt 2):941-950. [Content Brief]
[2]. Ameeramja J, et al. Protocatechuic acid methyl ester modulates fluoride induced pulmonary toxicity in rats. Food Chem Toxicol. 2018 Aug;118:235-244. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.9471 mL | 29.7357 mL | 59.4714 mL | 148.6785 mL |
| 5 mM | 1.1894 mL | 5.9471 mL | 11.8943 mL | 29.7357 mL | |
| 10 mM | 0.5947 mL | 2.9736 mL | 5.9471 mL | 14.8679 mL | |
| 15 mM | 0.3965 mL | 1.9824 mL | 3.9648 mL | 9.9119 mL | |
| 20 mM | 0.2974 mL | 1.4868 mL | 2.9736 mL | 7.4339 mL | |
| 25 mM | 0.2379 mL | 1.1894 mL | 2.3789 mL | 5.9471 mL | |
| 30 mM | 0.1982 mL | 0.9912 mL | 1.9824 mL | 4.9560 mL | |
| 40 mM | 0.1487 mL | 0.7434 mL | 1.4868 mL | 3.7170 mL | |
| 50 mM | 0.1189 mL | 0.5947 mL | 1.1894 mL | 2.9736 mL | |
| 60 mM | 0.0991 mL | 0.4956 mL | 0.9912 mL | 2.4780 mL | |
| 80 mM | 0.0743 mL | 0.3717 mL | 0.7434 mL | 1.8585 mL | |
| 100 mM | 0.0595 mL | 0.2974 mL | 0.5947 mL | 1.4868 mL |
Methyl 3,4-dihydroxybenzoate Related Classifications
HY-Z0548 Related Classifications
Powered by Bioz